Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

The author has participated in a Phase II clinical trial with Technosphere insulin and received lecturing fees from Pfizer Inc. and NovoNordisk. The author has no other relevant affiliations or ...

While weight loss can result in reducing insulin resistance, improving the way you eat can also help to lower your insulin levels. The key is to choose foods that don't raise your insulin even more.

“The product has a patented spring-loaded system that drives insulin through a small opening in a nozzle, virtually pain free.” The device uses high pressure dispersion through the skin.

Each medication will vary in terms of how long it stays in the body and how quickly it begins working. Insulin may be inhaled or injected into the skin with a syringe or pen. Afrezza (inhaled insulin) ...

The Sansum Diabetes Research Institute, a Santa Barbara-based nonprofit, turned 75 years old on May 20 in 2019. (file photo) In an effort to change the label on its main product, Afrezza, and equip ...

Diabetes management platform developer One Drop is to feature in a new trial investigating MannKind’s inhalable insulin, Afrezza. Named the A-ONE study, the trial will couple the use of One Drop ...

An FDA committee has given an overwhelming recommendation to new inhaled insulin treatment Afrezza. MannKind Corporation has spent years and many millions of dollars in developing the novel ...